Altamira Therapeutics (Altamira Therapeutics) Interest Expense

: $-1.17 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Altamira Therapeutics's interest expense for the six months ended in Dec. 2023 was $ -0.58 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.17 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Altamira Therapeutics's Operating Income for the six months ended in Dec. 2023 was $ -1.54 Mil. Altamira Therapeutics's Interest Expense for the six months ended in Dec. 2023 was $ -0.58 Mil. Altamira Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Altamira Therapeutics Interest Expense Historical Data

The historical data trend for Altamira Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.03

-0.15

-0.02

-0.97

-1.19

Altamira Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense																0.17	-0.39	-0.57	-0.59	-0.58

Altamira Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.17 Mil.

Altamira Therapeutics (NAS:CYTO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Altamira Therapeutics's Interest Expense for the six months ended in Dec. 2023 was $-0.58 Mil. Its Operating Income for the six months ended in Dec. 2023 was $-1.54 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was $0.00 Mil.

Altamira Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Altamira Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Altamira Therapeutics (Altamira Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altamira Therapeutics Ltd (NAS:CYTO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM11

Website

https://www.altamiratherapeutics.com

Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.